AMZN
Amazon.com, Inc.
AMZN has the edge over CURV overall, supported by lower modeled downside and stronger fundamentals.
CURV
Torrid Holdings Inc.
CURV's outlook is improving, though it still trails on the overall score.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CURV Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Weak |
CURV's revenue, profitability, cash flow and balance sheet are all currently under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
CURV PE Valuation
CURV has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 40x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over CURV on the outlook, with more favorable revenue expectations.
CURV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CURV to return to profit, with revenue holding steady. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over CURV on earnings quality, reporting a profit while its opponent remains loss making.
CURV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.06 | — |
| Q3 2026 | -$0.10 | -433% |
| Q2 2026 | -$0.13 | -244% |
| Q1 2026 | -$0.07 | -147% |
| Q4 2025 | -$0.02 | -113% |
| Q3 2025 | $0.03 | -79% |
| Q2 2025 | $0.09 | -25% |
| Q1 2025 | $0.15 | +36% |
| Q4 2024 | $0.16 | +60% |
CURV has swung to a loss: it lost $0.10 per share over the past year, after a profit the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CURV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over CURV on profitability, with a higher operating margin.
CURV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $231.7M | -12% |
| Q2 2026 | $245.8M | -7.6% |
| Q1 2026 | $236.2M | -14% |
| Q4 2025 | $235.2M | -11% |
| Q3 2025 | $262.8M | -7.7% |
| Q2 2025 | $266M | -4.9% |
| Q1 2025 | $275.6M | -6.1% |
| Q4 2024 | $263.8M | -4.2% |
CURV's revenue has slid since its 2022 peak: $232M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.3% | +2.4 points |
| Q2 2026 | 3.5% | -2.6 points |
| Q1 2026 | -2.1% | -3.4 points |
| Q4 2025 | 0.1% | -2.6 points |
| Q3 2025 | 3.9% | -3.3 points |
| Q2 2025 | 6% | -3.3 points |
| Q1 2025 | 1.3% | -0.1 points |
| Q4 2024 | 2.7% | +0.2 points |
CURV's operating margin was 6.3% last quarter, up 2.4 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CURV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3M | -121% |
| Q2 2026 | $5.7M | +$26.3M |
| Q1 2026 | -$9.3M | -191% |
| Q4 2025 | -$6.6M | -$1.1M |
| Q3 2025 | $14.6M | -61% |
| Q2 2025 | -$20.6M | -200% |
| Q1 2025 | $10.2M | +$12M |
| Q4 2024 | -$5.5M | -$1.9M |
CURV has the edge over AMZN on cash flow, with more consistent year-over-year improvement.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CURV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +667K shares |
| 1 year | -2.5% | -2.5M shares |
| 3 years | -3.8% | -4M shares |
| 5 years | -8.9% | -9.8M shares |
| Available history | -8.9% | -9.8M shares |
CURV has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $186,000 |
| Q1 2026 | — |
| Q4 2025 | $85,000 |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
CURV spent $271,000 buying back its own shares over the past year.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over CURV on leverage, with a lower net debt burden relative to earnings.
CURV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.2x | High |
| Q2 2026 | 5.2x | High |
| Q1 2026 | 4.4x | High |
| Q4 2025 | 3.9x | Elevated |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.1x | Elevated |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.6x | Moderate |
CURV's net debt is about 5.2 years of its operating earnings (EBITDA), up from 3.5 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CURV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.5 | Neutral |
| Stochastic | 35.0 | Neutral |
CURV's weekly RSI is 51 (neutral) and its Stochastic is 35 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CURV PE vs Consumer Cyclical Sector
| Metric | CURV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CURV has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over CURV on trend strength, trading above more of its moving averages.
CURV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.33 | 4.3% below |
| 20 week MA | $2.30 | 3% below |
| 50 week MA | $1.78 | 25% above |
| 100 week MA | $2.88 | 23% below |
| 200 week MA | $3.56 | 37% below |
CURV's trend is mixed: it's above one of its five weekly moving averages, and 37% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has finished higher in five of the last six years, two of them by more than 50%. It's up 15% so far in 2026.
CURV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $26.6 | $10.1 | -62% |
| 2022 | $10.1 | $3.02 | -70% |
| 2023 | $3.02 | $5.77 | +91% |
| 2024 | $5.77 | $5.28 | -8.5% |
| 2025 | $5.28 | $1.04 | -80% |
| 2026 YTD | $1.04 | $2.23 | +114% |
CURV has the edge over AMZN on returns for 2026, with the stronger performance.